All In Biotech

Drug Trial Radar · NCT07471217

[¹⁴C] Hydronidone Mass Balance Study

[¹⁴C] Hydronidone Mass Balance Study in Chinese Healthy Adult Male Participants

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Apr 17, 2026

Primary completion

May 6, 2026

Study completion May 6, 2026

Sponsor

Sponsor type
Industry
First posted
Mar 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

According to the "Technical Guidelines for Radioactive Labeled Human Mass Balance Studies" issued by the NMPA, human mass balance studies are an important component of clinical pharmacology research for innovative drugs, and it is recommended that mass balance studies be conducted for all new molecular entities. Therefore, to further clarify the absorption, metabolism, and excretion characteristics of Hydronidone in the human body, a \[¹⁴C\] Hydronidone mass balance study is planned in Chinese healthy adult male participants. This study aims to reveal the pharmacokinetic characteristics of Hydronidone and provide a reference for the rational use of the drug.

Conditions

  • Chronic Hepatitis B-related Liver Fibrosis

Interventions

  • [¹⁴C]HydronidoneDrug

    Enrolled participants fasted for at least 10 hours prior to dosing. On the morning of Day 1 (D1), a single oral dose of \[¹⁴C\]Hydronidone suspension (containing approximately 90 mg/100 μCi of \[¹⁴C\]Hydronidone) was administered under fasting conditions, with approximately 240 mL of water used for preparation and administration. Except for the water used for dosing, no water was permitted within 1 hour before and after administration. Participants remained in the isotope ward of the study center from dosing until Day 9 (D9), which could be shortened or extended depending on whether the sample collection termination criteria were met."

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative radioactive recovery in excreta (urine and feces) per collection periodTime frame: within 9 days after dosing
  2. Cumulative total radioactive recovery in excreta (urine and feces)Time frame: within 9 days after dosing
  3. Pharmacokinetic parameters of total radioactivity in plasma : CmaxTime frame: within 9 days after dosing
  4. Pharmacokinetic parameters of total radioactivity in plasma : TmaxTime frame: within 9 days after dosing
  5. Pharmacokinetic parameters of total radioactivity in plasma : t1/2Time frame: within 9 days after dosing
  6. Pharmacokinetic parameters of total radioactivity in plasma : MRTTime frame: within 9 days after dosing
  7. Pharmacokinetic parameters of total radioactivity in plasma : AUCTime frame: within 9 days after dosing
  8. Whole blood ratio of total radioactivity concentrationTime frame: within 9 days after dosing
  9. plasma ratio of total radioactivity concentrationTime frame: within 9 days after dosing
  10. Percentage of unchanged drug relative to total radioactivity exposure in plasmaTime frame: within 9 days after dosing
  11. Percentage of unchanged drug in urine relative to the administered dose (%Dose)Time frame: within 9 days after dosing
  12. Percentage of unchanged drug in feces relative to the administered dose (%Dose)Time frame: within 9 days after dosing
  13. Identification of major metabolites in plasmaTime frame: within 9 days after dosing
  14. Identification of major metabolites in urineTime frame: within 9 days after dosing
  15. Identification of major metabolites in fecesTime frame: within 9 days after dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Gaobo Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.